Articles Tagged With: eculizumab
-
Eculizumab for Refractory Myasthenia Gravis
Eculizumab, a monoclonal antibody that inhibits the C-5 complement terminal complex formation, is a safe and effective treatment for generalized myasthenia gravis with acetylcholine receptor auto-antibodies, even after failed treatment with other immunosuppressive regimens.
-
Eculizumab Shows Benefit in a Treatment Trial of NOSD
In a randomized, placebo-controlled trial of aquaporin-4 antibody-positive patients with neuromyelitis optica spectrum disorders, eculizumab demonstrated a decrease in the risk of a relapse. Patients could continue their other stable-dose immune suppressive therapies while enrolled in the trial.